Real-World Evidence (RWE) has emerged as a critical pillar in modern drug development, playing a pivotal role in regulatory submissions, post-marketing surveillance, and clinical decision-making. Derived from Real-World Data (RWD), including electronic health records, claims data, patient registries, and wearable devices, RWE provides insights into the safety, efficacy, and value of medical interventions in real-life clinical settings. This article explores the growing integration of RWE in drug development, emphasizing its regulatory acceptance and clinical relevance. We review methodological frameworks, case studies, and the evolving regulatory landscape led by the US FDA and the European Medicines Agency (EMA). The paper also discusses the strengths, limitations, and future prospects of RWE, arguing for its broader incorporation alongside randomized controlled trials (RCTs). Findings suggest that when rigorously designed and transparently reported, RWE studies can complement traditional clinical trials and significantly enhance patient-centered healthcare innovation.